MTQ Corporation SGX:M05 presents an attractive investment opportunity with its strong financials and potential for business turnaround.
Category: Case Studies
Wabash National Corporation (WNC:NYSE) – Driving Growth with Strong Financial Performance and a Solid Order Book
With an attractive valuation, positive financial outlook, and commitment to innovation, Wabash National $WNC is positioned for success.
Regis Corporation (NYSE:RGS) – Why I Remain Optimistic On Its Turnaround
Why I remain optimistic on Regis Corporation's ($RGS) successful turnaround through cost-cutting, and growth initiatives under new management.
Haw Par Group (SGX:H02) – A Simple Analysis II
I covered Haw Par Group back in 2019. Hence I think it is time to revisit this company which is trading at multi year lows.
Medpace Holdings Inc (NASDAQ:MEDP) – A High-Growth Investment Opportunity in the CRO Industry
Discover the potential of investing in Medpace Holdings Inc ($MEDP), a leading global CROin the healthcare industry.
uniQure NV (NASDAQ:QURE) – A Prognosis
We study uniQure NV ($QURE), a biotechnology company focused on developing gene therapies for rare diseases.
VolitionRx Limited (NYSE: VNRX) – Enters Commercial Stage for Nu.Q Vet Cancer Test
VolitionRx is commercially introducing a product with a huge addressable market. If successful, the market will rerate the stock.
Boustead SG (SGX:F9D) – Share Price Undervalued, But Lack of Near Term Catalyst
SOTP valuation shows Boustead's share price is undervalued. However, there may be a lack of near term catalyst for a rerate of share price.
uniQure N.V. (NASDAQ:QURE) – World’s Most Expensive Medicine
uniQure's AMT-061 is currently the world's most expensive drug. Here's why investing in $QURE may be rewarded with strong returns.
Five Interesting Earnings Reports At a Pivotal Point For The Market
We look at 5 intriguing earnings report I found during this earnings season